IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10 , including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10 , involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β , associated with the effective induction of foxp3+ regulatory T cells.
Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.